Patients with advanced lung cancer need to choose targeted drugs according to different situations. If lung cancer patients are found to have mutations in EGFR by genetic testing, they can take gefitinib, erlotinib, oseltinib and other targeted drugs orally. Patients with lung adenocarcinoma can also use bevacizumab, a targeted anti-tumor angiogenesis drug, which is often used in combination with chemotherapy drugs to achieve the best results. At present, two types of targeted drugs, namely Apatinib and Erlotinib, can be used in various types of lung cancer that have failed to be treated, and some patients can have certain efficacy after using them.